The drug industry has made a mint on immunotherapies for cancer, but those game-changing treatments don’t work for most people’s tumors. That has set in motion a scientific gold rush, as biotech companies search for molecules they can add to those drugs to turn them into universal therapies.

The latest promising candidate is TGF-beta, a thorny collection of proteins that regulates a host of bodily functions. Among them is the process by which the immune system decides to either attack cancerous growths or let them pass idly by.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy